Continuous Glucose Monitoring Systems Market Size, Share, Growth, and Industry Analysis, By Type (Transmitters & Receivers,Sensors,Insulin Pumps), By Application (Hospitals,Homecare,Diagnostics/ Clinics), Regional Insights and Forecast to 2035

Continuous Glucose Monitoring Systems Market Overview

The global Continuous Glucose Monitoring Systems Market size is projected to grow from USD 8793.89 million in 2026 to USD 10002.17 million in 2027, reaching USD 24636.99 million by 2035, expanding at a CAGR of 13.74% during the forecast period.

Continuous glucose monitoring (CGM) systems measure interstitial glucose levels at frequent intervals and transmit data to receivers, insulin pumps, or smartphones. As of 2023, the North America region held about 38.66 % share of the global CGM devices market. The use of real-time CGM is rising: in Germany and Austria, continuous monitoring usage among children increased from ~3 % in 2011 to ~16 % by 2016. Many CGM sensors operate with measurement intervals of 5 to 15 minutes, producing 96 to 288 data points per day. The top two manufacturers control the majority of installed base; outside those, newer entrants struggle to exceed ~5 % share. Demand arises from type 1 diabetes patients, as well as expanding type 2 and prediabetes populations, driving multiple device procurement cycles per year.

In the United States, adoption of CGM systems is especially strong among insulin-dependent diabetics. It is estimated that fewer than 10 % of Americans with diabetes currently use CGM systems, but those who do generally replace sensors every 7 to 14 days. The U.S. share of the North American CGM market exceeds 80 %. In U.S. clinical studies, users of CGM often achieve HbA1c improvements of 0.5 to 1.0 percentage point, with ~16 % relative reduction in hypoglycemia events. The FDA has recently cleared over-the-counter CGM models, as one manufacturer launched an OTC patch version available in consumer retail for 2-week and 4-week durations. These developments extend CGM penetration beyond insulin users to wellness and type 2 segments.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 60 % of insulin users adopt CGM for better glycemic control
• Major Market Restraint: 30 % of physicians cite cost and reimbursement barriers
• Emerging Trends: 25 % of new CGM launches include noninvasive or sensorless features
• Regional Leadership: North America ~38.7 %, Europe ~28 %, Asia-Pacific ~25 %
• Competitive Landscape: Top 2 manufacturers control ~80 % of market
• Market Segmentation: Sensors ~50 %, transmitters & receivers ~30 %, pumps ~20 %
• Recent Development: One leading CGM maker launched 15-day sensor in 2025

Continuous Glucose Monitoring Systems Market Latest Trends

In the Continuous Glucose Monitoring Systems Market, integration of wearables, data analytics, and consumer access is pushing evolution. Sensor units now last 10 to 15 days in many new models, compared to earlier 7-day devices. In 2024, ~25 % of new CGM product announcements included noninvasive or minimally invasive sensor technology, though adoption remains low. Hybrid closed-loop systems combining CGM and insulin pumps represent over 20 % of new device purchases in developed markets. Over-the-counter (OTC) CGM models are emerging: one manufacturer launched a patch for non-insulin users with 2-week and 4-week versions. In Europe, ~50 % of CGM users still rely on prescription models, but OTC availability is expected to shift that ratio.

Continuous Glucose Monitoring Systems Market Dynamics

DRIVER

"Rising prevalence of diabetes and demand for real-time glucose control"

The global diabetic population exceeds 537 million individuals; type 2 diabetes accounts for ~90 %. Among insulin users, ~60 % adopt CGM systems to reduce hypoglycemia risk and optimize dosing. Frequent monitoring offers more than 96 data points per day, enabling fine adjustments. Studies report CGM users reduce hypoglycemic episodes by ~30 %. The move toward closed-loop or automated insulin delivery systems depends on CGM input; over 20 % of new pump systems integrate CGM in 2024. Many clinicians now recommend CGM for gestational diabetes or pregnancy; uptake in these groups increased ~12 % year over year. The push for remote monitoring and telemedicine also boosts demand: during the COVID period, CGM adoption jumped ~20 % in some markets. These forces feed the Continuous Glucose Monitoring Systems Market Growth, expanding beyond traditional insulin users into broader glucose-monitoring segments.

RESTRAINT

"Cost, reimbursement barriers, and clinician resistance"

Cost barriers persist: sensors and transmitters must be replaced regularly (every 7 to 15 days), leading ~30 % of physicians to cite cost as a deterrent. Many payers limit reimbursement to insulin-dependent users; in non-insulin type 2, authorization is granted in only ~20 % of claims. Some clinicians resist adoption: ~25 % prefer fingerstick methods due to familiarity and skepticism of sensor accuracy. Sensor failures or calibration errors occur in ~5 % of units, reducing confidence. Some users report skin irritation or patch adhesion issues in ~15 % of cycles. Geographic reimbursement disparities are sharp: in some countries, only ~10 % of diabetics have insurance coverage for CGM. These constraints hamper faster uptake, especially in low- and middle-income regions.

OPPORTUNITY

"OTC models, noninvasive sensors, and expansion in type 2 market"

Over-the-counter CGM models target non-insulin users and wellness markets; in 2025, a major manufacturer launched such patches, available in 2-week and 4-week versions. These extend access beyond ~30 % of insulin users to many more. Noninvasive sensor development—currently ~25 % of new launches—offers pain-free monitoring options, enhancing adoption in younger and health-conscious populations. Type 2 diabetes remains underpenetrated: only ~15 % of CGM users are type 2 non-insulin patients; scaling in this group offers vast opportunity. Emerging markets in Asia, Latin America, and Middle East represent ~25 % combined share presently; with lower cost and regulatory support, uptake can rise. Integrated software, AI analytics, and telehealth revenue models (with ~30 % of devices including cloud services) can further monetize data beyond hardware. Wearable combinations (smartwatches + sensor) may embed CGM into mainstream devices.

CHALLENGE

"Accuracy, calibration, regulatory barriers, and competitive pricing"

Calibration drift and sensor accuracy remain concerns: ~5 % of CGM devices report deviations >10 %. Noninvasive prototypes often lack regulatory approvals; few have entered mass commercialization. Regulatory pathways differ: some devices require class II medical device clearance; ~20 % of sensor makers cite regulatory complexity as a barrier. Pricing pressure is intense: ~50 % of CGM tenders are awarded on lowest total cost rather than performance. Success in OTC models depends on user education; up to ~20 % of new OTC users drop usage due to poor understanding. Sensor adhesion and wear comfort issues affect ~15 % of cycles. Legacy glucose monitoring players resist cannibalization; some regions delay reimbursement listing by ~2 years. These challenges make adoption uneven.

Continuous Glucose Monitoring Systems Market Segmentation

The Continuous Glucose Monitoring Systems Market Market is segmented by type and application. Type segmentation includes transmitters & receivers, sensors, and insulin pumps. Application segments are hospital settings, homecare, and diagnostics/clinics. Sensor modules account for ~50 % of device component value, transmitters & receivers ~30 %, and integrated pump units ~20 %. Among applications, homecare leads with ~60 % usage, hospitals ~25 %, and diagnostics/clinics ~15 %.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Transmitters and Receivers : Transmitters and receivers contribute about 30 percent of the overall market. Nearly 25 percent of new transmitters include Bluetooth or NFC connectivity, while 60 percent of homecare users depend on mobile integration. The average transmitter lifespan ranges from one to three years, and roughly 20 percent of hospitals use shared transmitter units for multiple patients.

Sensors : Sensors lead the market with roughly 50 percent share. Around 80 percent of sensors use electrochemical technology, with optical and enzymatic types covering the remaining 20 percent. The standard wear duration ranges from seven to fifteen days, and accuracy averages between eight and twelve percent MARD. Noninvasive sensors remain under five percent of total demand but are gradually expanding across high-income markets.

Insulin Pumps : Insulin pumps represent nearly 20 percent of the Continuous Glucose Monitoring Systems Market Market. About 35 percent of insulin pump users operate hybrid closed-loop systems that reduce hypoglycemia events by nearly 30 percent. In 2024, around 20 percent of newly introduced insulin pumps included full CGM compatibility, while hospital adoption reached 10 percent of inpatient diabetes care programs.

BY APPLICATION

Hospitals : Hospitals account for around 25 percent of global CGM utilization. Approximately 15 percent of major hospitals in the United States use CGM systems for inpatient diabetes management. Sensor replacement typically occurs every five to seven days, and about 30 percent of hospital contracts are multi-year supply agreements. Shared transmitter setups reduce overall device costs by up to 20 percent.

Homecare : Homecare dominates the market with nearly 60 percent of total CGM use. Around 70 percent of homecare users are insulin-dependent, while 15 percent are non-insulin type 2 patients. Approximately 40 percent prefer factory-calibrated or no-calibration sensors, and 65 percent of transmitters connect directly to mobile applications. Over-the-counter CGM models introduced in 2025 represent about 20 percent of new user installations.

Diagnostics and Clinics : Diagnostics and clinics represent about 15 percent of total market share. Roughly 25 percent of clinics utilize reusable sensors, while 30 percent employ cloud-based dashboards for patient data tracking. Short-term seven- to fourteen-day monitoring sessions account for 80 percent of clinical CGM use, and around 20 percent of these programs focus on therapy adjustments and patient education.

Continuous Glucose Monitoring Systems Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America commands about 38.66 % of the global CGM device market share. The United States and Canada are major markets, with the U.S. dominating at ~80 % share of the region. U.S. CGM unit shipments in 2023 exceeded 5 million sensors across users. Institutional adoption in U.S. hospitals is rising: ~15 % of large academic hospitals now use CGM in inpatient diabetes care wards. OTC CGM models launched in 2025 expanded reach: one device is priced for 2-week and 4-week wear durations. The region also leads in reimbursement: ~40 % of U.S. states approve CGM for non-insulin type 2 users. Many U.S. users replace transmitters over 2 to 3 years; sensors replaced every 7 to 15 days. The U.S. CGM market is technologically advanced: ~30 % of devices support smartphone cloud integration and AI alerts. North America remains the global innovation hub and highest value market segment.

EUROPE

Europe holds approximately 28 % of global CGM market share, with leaders in Germany, UK, France, Italy, and Spain. In Germany and Austria, continuous monitoring usage among children rose from ~3 % to ~16 % between 2011 and 2016, demonstrating adoption trends. European national health systems increasingly reimburse CGM in insulin-dependent diabetes; in many countries ~50 % of new insulin-user patients qualify. Sensor replacement cycles align with global norms: 10 to 14 day sensors are common. European CGM reimbursement remains variable: in ~20 % of EU countries, CGM is covered only under specific criteria. OTC approvals lag the U.S., but some European countries granted regulatory clearance for nonprescription devices in 2024. Cloud-based data and cross-border interoperability are key: ~25 % of EU devices support multi-language app platforms. Many European clinics use CGM for structured education programs: ~20 % of endocrinology centers deploy short-term CGM for training and insulin adjustment.

ASIA-PACIFIC

Asia-Pacific region commands ~25 % of CGM deployment. Countries like China, Japan, South Korea, India, and Australia lead. China represents ~40 % of APAC share, Japan ~20 %, India ~15 %, South Korea ~10 %, and the rest Southeast Asia ~15 %. The region’s diabetic population is large: China has over 100 million diabetics, increasing CGM demand. Unit growth in APAC was ~18 % in 2024, especially in urban and affluent regions. However, reimbursement is more limited: less than ~30 % of patients in Asia have insurance support for CGM. Many users pay out-of-pocket, which limits adoption. Some countries use imported devices, while local manufacturers aim to supply ~20 % of domestic demand. Indian users adopt 10-day sensors (~60 %) or 14-day units (~30 %), with ~10 % using newer extended sensors.

MIDDLE EAST & AFRICA

Middle East & Africa currently holds ~8 % of global CGM share. The Gulf region (UAE, Saudi Arabia, Qatar) leads regional adoption. In the GCC, ~12 % of diabetics use CGM systems, with coverage by employer health plans in ~25 % of contracts. South Africa and Israel contribute ~30 % of regional demand outside GCC. In many African countries, CGM penetration is <1 % due to cost and infrastructure barriers. Replacement cycles are longer: sensors sometimes worn 14 days or more to reduce cost burden. Clinical pilot programs exist in ~5 countries, deploying CGM for education or gestational diabetes.

List of Top Continuous Glucose Monitoring Systems Companies

• Texas Instruments Inc • Medtrum Technologies Inc. • Senseonics Holdings, Inc. • Echo Therapeutics, Inc. • Ypsomed Group • AgaMatrix Inc. • Nemaura Medical Inc. • LifeScan Inc. • WaveForm Technologies, Inc. • NXP Semiconductors N.V. • Johnson & Johnson Services Inc. • F. Hoffmann-La Roche Ltd. • STMicroelectronics • Novo Nordisk A/S • ViCentra B.V. • Abbott Laboratories • Menarini Diagnostics S.r.l. • DexCom, Inc. • GlySens Incorporated • Tandem Diabetes Care, Inc. • Insulet Corporation • Bayer AG • Medtronic PLC

Top Two Companies with the Highest Market Share:

Abbott Laboratories – Abbott’s Libre CGM platforms command approximately 40 % to 45 % share in many mature markets, making it one of the dominant players in continuous glucose monitoring systems globally. DexCom, Inc. – DexCom’s G6 and G7 systems hold ~30 % to 35 % share in key insulin-user segments and are frequently reported as the second largest in global CGM installations.

Investment Analysis and Opportunities

Investment in the Continuous Glucose Monitoring Systems Market is growing as diabetes prevalence, wearable health, and telemedicine converge. The global diabetic population is over 537 million, providing a large base for CGM adoption. The top two companies already hold ~80 % of market share, but opportunities lie in niche devices, sensor innovation, and emerging markets. Over-the-counter CGM models open new non-insulin user segments; one firm launched OTC patches in 2025 targeting wellness users. Noninvasive sensor technology is emerging: ~25 % of new prototypes aim for noninvasive measurements. In Asia-Pacific and Middle East & Africa regions (~33 % and ~8 % shares respectively), low penetration suggests room for expansion.

New Product Development

New product development in the CGM market is centered on extended wear sensors, noninvasive systems, integration with wearables, and sensor performance improvements. Some new sensors now support 10- to 15-day wear periods (vs older 7-day models). Over 25 % of new CGM launches in 2024–2025 include noninvasive or minimal-invasive sensor technology. Hybrid closed-loop systems combining insulin pumps and CGM with AI algorithms now account for over 20 % of new system offerings. Many new transmitters support Bluetooth LE, NFC, or cloud sync; ~30 % of new transmitter units include smartphone integration. Another trend is embedded data analytics and prediction: ~15 % of new devices include predictive hypoglycemia alerts. Sensor accuracy improvements aim for MARD < 8 %; ~10 % of new prototypes achieve that benchmark in trials.

Five Recent Developments

• Abbott launched an over-the-counter continuous glucose monitoring patch named “Lingo” in the U.S. for non-insulin users, offering 2-week and 4-week versions.
• DexCom secured FDA clearance for a new G7 system offering up to 15.5 days of sensor wear in trials.
• Several CGM firms introduced sensor models with factory calibration (no fingerstick) in 2024, now comprising ~20 % of new device launches.
• Integration deals ramped: ~25 % of new CGM contracts in 2025 include cloud analytics subscription bundling.
• Noninvasive sensor prototypes have advanced in Europe: in 2024–2025, >5 prototypes entered pilot scaling phases, though none yet captured major share.

Report Coverage

This Continuous Glucose Monitoring Systems Market Market Report covers global device segmentation, application breakdown, and regional performance. It includes Continuous Glucose Monitoring Systems Market Market Analysis of growth drivers, restraints, opportunities, and challenges. The report presents Continuous Glucose Monitoring Systems Market Market Trends such as extended wear sensors, OTC models, and hybrid closed-loop systems. It outlines Continuous Glucose Monitoring Systems Market Market Size and share distribution across North America, Europe, Asia-Pacific, and Middle East & Africa.

Continuous Glucose Monitoring Systems Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 8793.89 Million in 2026
Market Size Value By	USD 24636.99 Million by 2035
Growth Rate	CAGR of 13.74% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Transmitters & Receivers Sensors Insulin Pumps By Application : Hospitals Homecare Diagnostics/ Clinics
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample